18F-FDG PET/CT radiomics predicts brain metastasis in I-IIIA resected Non-Small cell lung cancer

被引:3
|
作者
Zheng, Zhonghang [1 ,2 ]
Wang, Jie [1 ,2 ]
Tan, Weiyue [1 ,2 ]
Zhang, Yi [1 ,2 ]
Li, Jing [1 ,2 ]
Song, Ruiting [1 ,2 ]
Xing, Ligang [3 ]
Sun, Xiaorong [2 ]
机构
[1] Shandong First Med Univ & Shandong Acad Med Sci, Dept Grad, Jinan, Shandong, Peoples R China
[2] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Nucl Med, Jinan 250117, Shandong, Peoples R China
[3] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Shandong, Peoples R China
基金
中国国家自然科学基金;
关键词
Positron emission tomography; computed; tomography; Radiomics; Brain metastases; Non-small cell lung cancer; Prediction model; PROPHYLACTIC CRANIAL IRRADIATION; RISK; EGFR; MUTATION; IMAGES;
D O I
10.1016/j.ejrad.2023.110933
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective: To establish 18F-FDG PET/CT radiomics model for predicting brain metastasis in non-small cell lung cancer (NSCLC) patients.Methods: This research comprised 203 NSCLC patients who had received surgical therapy at two institutions. To identify independent predictive factors of brain metastasis, metabolic indicators, CT features, and clinical fea-tures were investigated. A prediction model was established by incorporating radiomics signature and clinico-pathological risk variables. The suggested model's performance was assessed from the perspective of discrimination, calibration, and clinical application.Results: The C-indices of the PET/CT radiomics model in the training, internal validation, and external validation cohorts were 0.911, 0.825 and 0.800, respectively. According to the multivariate analysis, neuron-specific enolase (NSE) and air bronchogram were independent risk factors for brain metastasis (BM). Furthermore, the combined model integrating radiomics and clinicopathological characteristics related to brain metastasis per-formed better in terms of prediction, with C-indices of 0.927, 0.861, and 0.860 in the training, internal vali-dation, and external validation cohorts, respectively. The decision curve analysis (DCA) suggested that the PET/ CT nomogram was clinically beneficial.Conclusions: A predictive algorithm based on PET/CT imaging information and clinicopathological features may accurately predict the probability of brain metastasis in NSCLC patients following surgery. This presented doctors with a unique technique for screening NSCLC patients at high risk of brain metastasis.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Evaluation of gross tumor size using CT, 18F-FDG PET, integrated 18F-FDG PET/CT and pathological analysis in non-small cell lung cancer
    Yu, Hui Ming
    Liu, Yun Fang
    Hou, Ming
    Liu, Jie
    Li, Xiao Nan
    Yu, Jin Ming
    EUROPEAN JOURNAL OF RADIOLOGY, 2009, 72 (01) : 104 - 113
  • [32] Pre-radiotherapy assessment of non-small cell lung cancer with 18F-FLT PET/CT or 18F-FDG PET/CT
    Xu, Xiaoting
    Nie, Liangqin
    Yao, Yimin
    Tu, Yu
    Zhou, Juying
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (06): : 9252 - 9260
  • [33] 18F-FDG PET/CT total lesion glycolysis is associated with circulating tumor cell counts in patients with stage I to IIIA non-small cell lung cancer
    Avella, Diego M.
    Manjunath, Yariswamy
    Singh, Amolak
    Deroche, Chelsea B.
    Kimchi, Eric T.
    Staveley-O'Carroll, Kevin F.
    Mitchem, Jonathan B.
    Kwon, Eric
    Li, Guangfu
    Kaifi, Jussuf T.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (03) : 515 - 521
  • [34] [18F]FAPI adds value to [18F]FDG PET/CT for diagnosing lymph node metastases in stage I-IIIA non-small cell lung cancer: a prospective study
    Li, Youcai
    Zhang, Yin
    Guo, Zhihua
    Hou, Peng
    Lv, Jie
    Ke, Miao
    Liu, Shaoyu
    Li, Siwen
    Yin, Weiqiang
    He, Jianxing
    Wang, Xinlu
    CANCER IMAGING, 2024, 24 (01)
  • [35] Thoracic staging with 18F-FDG PET/MR in non-small cell lung cancer - does it change therapeutic decisions in comparison to 18F-FDG PET/CT?
    Schaarschmidt, Benedikt M.
    Grueneisen, Johannes
    Metzenmacher, Martin
    Gomez, Benedikt
    Gauler, Thomas
    Roesel, Christian
    Heusch, Philipp
    Ruhlmann, Verena
    Umutlu, Lale
    Antoch, Gerald
    Buchbender, Christian
    EUROPEAN RADIOLOGY, 2017, 27 (02) : 681 - 688
  • [36] Thoracic staging with 18F-FDG PET/MR in non-small cell lung cancer – does it change therapeutic decisions in comparison to 18F-FDG PET/CT?
    Benedikt M. Schaarschmidt
    Johannes Grueneisen
    Martin Metzenmacher
    Benedikt Gomez
    Thomas Gauler
    Christian Roesel
    Philipp Heusch
    Verena Ruhlmann
    Lale Umutlu
    Gerald Antoch
    Christian Buchbender
    European Radiology, 2017, 27 : 681 - 688
  • [37] Role of 18F-FDG PET in Assessment of Response in Non-Small Cell Lung Cancer
    Hicks, Rodney J.
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50 : 31S - 42S
  • [38] Cyclin A and Cyclin E Expression in Resected Non-small Cell Lung Cancer Stage I-IIIA
    Kosacka, Monika
    Piesiak, Pawel
    Porebska, Irena
    Korzeniewska, Anna
    Dyla, Tomasz
    Jankowska, Renata
    IN VIVO, 2009, 23 (04): : 519 - 525
  • [39] Prognostic role of baseline 18F-FDG pet/CT in stage I and stage ii non-small cell lung cancer
    Dondi, Francesco
    Albano, Domenico
    Bellini, Pietro
    Cerudelli, Elisabetta
    Treglia, Giorgio
    Bertagna, Francesco
    CLINICAL IMAGING, 2023, 94 (71-78) : 71 - 78
  • [40] Physiologic Colonic Uptake of 18F-FDG on PET/CT Predicts Immunotherapy Response in Patients with Advanced Non-small Cell Lung Cancer
    Regis, Claudine
    Cvetkovic, Lena
    Leblond, Antoine
    Malo, Julie
    Meriem, Messaoudene
    Belkaid, Wiam
    Routy, Bertrand
    Juneau, Daniel
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61